Fogorvosi szemle, 2006 (99. évfolyam, 1-6. szám)

2006-06-01 / 3. szám

106 FOGORVOSI SZEMLE 99. évf. 3. sz. 2006. 49. Gabre P, Norrman C, Birkhed D: Oral sugar clearance in individu­als with oral motor dysfunctions. Caries Res 2005. 39: 357-362. 50. Goodwin T, Murphy MD: Hyperemesis gravidarum. Clin Obst/Gyn Ambulatory Obs Manage 1998; 41: 597-605. 51. Grabowski J: Clonidine treatment of clozapine-induced hypersa­livation. J Clin Psychoharmacol 1992; 12: 69-70. 52. Grewal DS, Hirandani NL, RangwallaZA, Sheoda JH: Transtym­­panic neurectomies for control of drooling. Auris Nasus Larynx 1984; 11: 109-114. 53. Guntinas-LichiusO, EckelH: Temporary reduction of salivation in laryngectomy patients with pharyngocutaneous fistulas by botulinum toxin A injection. Laryngoscope 2002; 112,187-189. 54. Hagenah J, Kahl KG, Steinlechner S, Lencer R, Klein C: Die Behandlung derSialorrhö mit Botulinum-Toxin. Nervenarzt2005; 76: 418-425. 55. Hantsch RJ, First ER: Cessation of sialorrhoea in a post-stroke patient following botulinum toxin type A injections: a case report. Am J Rhys Med Rehab 2005; 84: 223. 56. Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B: Use of radiotherapy for control of sialorrhoea in patients with amyo­trophic lateral sclerosis. J Otolaryngol2001 ; 30: 242-245. 57. Harris MM, Dignam PF: A non-surgical method of reducing drool­ing in cerebral palsied children. Dev Med Child Neurol 1980; 22: 293-299. 58. Heider A, Engels B, Hartmann-Klosterkotter U, Kress M, Nie­­derle N: Hypersalivation as a leading symptom of neoplastic menin­­giosis in highly malignant non-Hodgkin’s lymphoma. Dtsch Med Wochenschr 1993; 118:19-22. 59. Hendrickson RG, Morocco AP, Greenberg Ml : Pilocarpine toxicity and the treatment of xerostomia. J Emer Med 2004: 26: 429-432. 60. Hinkes R, QuesadaTV, Currier MB, Gonzales-BlancoM: Aspira­tion pneumonia possibly secondary to clozapine-induced sialorrhoea. J Clin Psychopharmacol 1996; 16: 462-463. 61. Hockstein NG, Samadi DS, Gendron K, Handler SD: Sialorrhoea: a management challange. Am Fam Phys 2004; 69: 2628-2634. 62. Hussein I, Kershaw AE, Tahmassebi JF, Fayle SA: The manage­ment of drooling in children and patients with mental and physical disabilities: aliterature review. Int J Pediatr Dent 1998; 8: 3-11. 63. Hyson HC, Johnson A, Jog MS: Survey of sialorrhoea in parkin­sonian patients in southwestern Ontario. Can J Neurol Sei 2001 ; 28: 546-547. 64. Hyson HC, Johnson AM, Jog MS: Sublingual atropine for sial­orrhoea secondary to parkinsonism: a pilot study. Mov Dis 2002; 17: 1318-1320. 65. Iammatteo PA, Tombly C, Luecke L: The effect of mouth closure on drooling and speech. AmJOccup Ther 1990; 44: 686-691. 66. Johnston BT, Li Q, Castell JA, Castell DO: Swallowing and esophageal function in Parkinson’s disease. AmJ Gastroenterol 1995; 90: 1741-1746. 67. Jongerius PH, vanTielP, van Limbeck J, Gabreëls FJM, Rotteveel JJ : A systemic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Childhood2003; 88: 911-914. 68. Jongerius PH, van Limbeek J, Rotteveel JJ: Assessment of sali­vary flow rate: biologic variation and measure error. Laryngoscope 2004; 114: 1801-1804. 69. Kass R, Kochar G, Lippman M: Adult respiratory distress from organophosphate poisoning. Am J Emer Med 1991; 9: 32-33. 70. Klem C, Mair EA: Four-duct ligation. A simple and effective treat­ment for chronic aspiration from sialorrhoea. Arch Otolaryngol Head NeckSurg 1999; 125: 796-800. 71. KoheilR, Sochaniwskyj AE, BablichK, Kenny DJ, Milner M: Bio­feedback techniques and behaviour modification in the conservative remediation of drooling by children with cerebral palsy. Dev Med Child A/euro/1987; 29: 19-26. 72. Lancioni GE, Brouwer JA, Coninx F: Automatic-cueing to reduce drooling: a long-term follow up with two mentally handicapped per­sons. J Behav Ther Exp Physchiat 1994; 25:149-152. 73. Lashley KL: Changes in the amount of salivary secretion associat­ed with cerebral lesions. Am J Physiol 1917; 43: 62-72. 74. Lewis DW, Fontana C, Mehallich LK, Everett Y: Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev Med Child Neurol 1994; 36: 484-486. 75. Lieblich S: Episodic supersalivation (idiopathic paroxysmal sial­orrhoea): Description of a new clinical syndrome. Oral Surg Oral Med Oral Pathol 1989; 68: 159-161. 76. Limbrock GJ, Fischer-Brandies H, Avalle C: Castillo-Morales’ orofacial therapy: treatment of 67 children with Down syndrome. Dev Med Child Neurol 1991 ; 33: 296-303. 77. Lin CL, Yang CT, Pan KY, Huang CC: Most common intoxication in nephrology ward organophosphate poisoning. Ren Fail2004; 26: 349-354. 78. Lipkin P: Epidemiology of the developmental disabilities. In: Capu- te AJ, Accardo PJ (eds.): Development Disabilities in Infancy and Childhood. Paul Brookes, Baltimore, 1991. 79. Lombeck I, Menzel H, Frosch D: Acute selenium poisoning of a 2-year-old child. EurJ Ped/'af1987; 146: 308-312. 80. Macknin ML, PiedmonteM, Jakobs J, Scibinski C: Symptoms asso­ciated with infant teething: a prospective study. Pediatrics2000; 105: 747-752. 81. Mankarios LA, Bottrill IA, Huchzermyer PM, Bailey CM: Long­term follow-up of submandibular duct rerouting for the management of sialorrhoea in the pediatric population. Otolaryngol Head Neck Surg 1999; 120:303-307. 82. Marini JL: Pilocarpine, a non-hallucinogenic cholinergic ago­nist, elicits limb flicking in cats. Pharmacol Biochem Behav 1981; 15:865-900. 83. Mencías E, Ballesteros S: Ecstasy ingestion: a pediatric case report of severe complications. Toxicol Lett 1996; 88: 54. 84. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M: Treatment of sialorrhoea wit glycopyrrolate: a double-blind, dose­ranging study Arch Pediatr Adolesc Med2000; 154:1214-1218. 85. Moulding MB, Koroluk LD: An intraoral prosthesis to control drooling in a patient with amyotrophic lateral sclerosis. Spec Care Dentist 1991; 11:200-202. 86. Mullins WM, Gross CW, Moore JM: Long-term follow-up of tympanic neurectomy for sialorrhoea. Laryngoscope 1979; 89: 1219-1223. 87. Myer CM: Sialorrhoea. Pediat Clin North Am 1989; 6:1495-1500. 88. Olsen AK, Sjögren P: Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. J Pain Sympt Manage 1999; 18: 300- 302. 89. Ondó WG, Hunter C, Moore W: A double-blind placebo-controlled trial of botulinum toxin B for sialorrhoea in Parkinson’s disease. Neu­rology 2004\ 62: 37-40. 90. Ondzotto G, Galiba J: Hypersialorrhoea in mental retardation: interest of salivary denervation. Odonto-Stomatoloqie Tropicale 200 27: 27-28. 91. Osborne JG, Gatling JH, Wells J, Blakelock H, Peine H, Jenson W: Observation and measurement of drooling by people with mental retardation. Mental Retardation 1994; 32: 288-298. 92. Porta M, Gamba M, Bertacci G, Vaj P: Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurologic disorders. J Neurol Neurosurg Psychiatry 2001 ; 70: 538-540. 93. Potulska A, Friedman A: Controlling sialorrhoea: a review of avai­lable treatment options. ExpOpin Pharmacother2005\ 6:1551-1554. 94. Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED: Cli­nical spectrum of secondary parkinsonism in childhood: A reversible disorder. Pediat Neurol 1994; 10:131-140. 95. Proulx M, deCourval FP, Wiseman MA, PanissetM: Salivary pro­duction in Parkinson’s disease. Mov Dis 2005; 20: 204-207. 96. Puskulian L: Salivary electrolyte changes during the normal menstrual cycle. J Dent Res 1972; 51:1212-1216. 97. RabinowitzT, Frankenburg FR, CentorrinoF, Kandó J: The effect of clozapine on salivary flow rate: a pilot study. Biol Psychiatry 1996; 40: 1132-1134. 98. Racette BA, Good L, Sagitto S, Perlmutter JS: Botulinum toxin B reduces sialorrhoea in parkinsonism. Mov Dis 2003; 18: 1059- 1061.

Next

/
  • Elrendezés
  • Igazítás
  • Forgatás
Oldalképek
Tartalom